Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Hans Dooms

Concepts (176)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Receptors, Interleukin-7
6
2026
28
2.110
Why?
T-Lymphocytes, Regulatory
8
2026
415
1.670
Why?
Immunologic Memory
8
2021
369
1.530
Why?
Scleroderma, Systemic
2
2026
124
1.400
Why?
Interleukin-2
12
2012
434
1.360
Why?
Autoimmunity
5
2026
925
1.200
Why?
Th1 Cells
5
2026
139
1.190
Why?
T-Lymphocyte Subsets
6
2026
416
1.170
Why?
CD4-Positive T-Lymphocytes
11
2021
1150
1.160
Why?
Interleukin-7
6
2017
66
1.010
Why?
Forkhead Transcription Factors
4
2026
209
1.010
Why?
Diabetes Mellitus, Type 1
7
2026
3930
0.970
Why?
Adoptive Transfer
3
2021
197
0.780
Why?
STAT5 Transcription Factor
2
2021
51
0.710
Why?
Lymphocyte Activation
13
2021
1137
0.700
Why?
Hepatitis A Virus Cellular Receptor 2
2
2018
27
0.660
Why?
Antibodies, Monoclonal
3
2019
1512
0.650
Why?
Programmed Cell Death 1 Receptor
3
2018
268
0.640
Why?
Interleukin-7 Receptor alpha Subunit
1
2019
11
0.580
Why?
T-Lymphocytes
5
2013
2012
0.550
Why?
Adjuvants, Immunologic
3
2007
245
0.530
Why?
Mice, Inbred NOD
4
2026
598
0.530
Why?
Cytokines
4
2023
2081
0.500
Why?
Lymphocytes
2
2018
379
0.490
Why?
Receptors, Immunologic
1
2018
210
0.490
Why?
Autoantigens
2
2019
426
0.480
Why?
Immunotherapy
2
2019
671
0.450
Why?
Interleukin-15
4
2012
96
0.420
Why?
Islets of Langerhans
1
2021
852
0.420
Why?
CD8-Positive T-Lymphocytes
3
2017
931
0.390
Why?
Mice
25
2026
18297
0.370
Why?
Interferon-gamma
4
2026
781
0.330
Why?
Animals
29
2026
38107
0.320
Why?
Autoimmune Diseases
1
2013
467
0.290
Why?
Signal Transduction
7
2021
5246
0.280
Why?
Pneumonia, Pneumococcal
2
2020
48
0.270
Why?
Mice, Knockout
8
2026
3125
0.260
Why?
Cell Differentiation
6
2020
1982
0.240
Why?
Antibodies, Blocking
2
2018
38
0.230
Why?
Th2 Cells
3
2023
179
0.230
Why?
Leukocytes, Mononuclear
2
2018
585
0.210
Why?
Flow Cytometry
3
2026
1163
0.210
Why?
Immune Tolerance
4
2013
386
0.200
Why?
Lupus Erythematosus, Systemic
1
2026
241
0.200
Why?
Disease Models, Animal
5
2020
4580
0.200
Why?
Immunity
2
2017
141
0.200
Why?
Cell Proliferation
5
2019
2502
0.190
Why?
Helminthiasis
1
2023
11
0.190
Why?
Apoptosis
4
2002
2439
0.190
Why?
Cells, Cultured
6
2017
4118
0.180
Why?
Cell Lineage
1
2002
377
0.160
Why?
Female
12
2026
79499
0.150
Why?
Mice, Inbred BALB C
6
2010
1244
0.140
Why?
Immunization, Secondary
1
1998
94
0.140
Why?
Mice, Transgenic
6
2012
2134
0.130
Why?
Antigens, Viral
1
1998
186
0.130
Why?
Immunity, Heterologous
1
2017
2
0.130
Why?
Immunization
1
2019
376
0.120
Why?
Macrophages, Alveolar
1
2020
377
0.120
Why?
Receptors, Interleukin-2
2
2008
64
0.120
Why?
Homeostasis
2
2013
646
0.120
Why?
Cell Survival
2
2013
1105
0.120
Why?
Antigens, CD
2
2017
560
0.120
Why?
CD40 Ligand
2
2012
32
0.110
Why?
Streptococcus pneumoniae
1
2017
187
0.110
Why?
Humans
15
2026
146342
0.110
Why?
Receptors, Antigen, T-Cell
3
2012
677
0.110
Why?
Lipid Metabolism
1
2017
533
0.100
Why?
Mitochondria
2
2017
997
0.100
Why?
4-1BB Ligand
1
2012
7
0.090
Why?
Isoantigens
1
2012
17
0.090
Why?
Phenotype
1
2021
3206
0.090
Why?
Antigens, Differentiation
1
2012
75
0.090
Why?
Gene Expression Regulation
4
2023
2599
0.090
Why?
Anemia, Hemolytic, Autoimmune
2
2010
17
0.080
Why?
Interleukin-2 Receptor alpha Subunit
2
2010
82
0.080
Why?
Energy Metabolism
1
2017
930
0.080
Why?
Polymorphism, Genetic
1
2013
612
0.080
Why?
Middle Aged
2
2026
36619
0.080
Why?
Vaccination
1
2019
1449
0.080
Why?
CD28 Antigens
2
2007
57
0.080
Why?
Adult
2
2026
41087
0.070
Why?
Mice, Inbred C57BL
7
2017
6034
0.070
Why?
Cell Death
2
2002
379
0.070
Why?
Lung
2
2020
4122
0.060
Why?
Male
3
2026
73396
0.060
Why?
Cell Separation
2
2012
300
0.050
Why?
Mitomycin
1
2004
31
0.050
Why?
Genetic Predisposition to Disease
1
2013
2488
0.050
Why?
Oxygen Consumption
2
2017
721
0.050
Why?
Ovalbumin
1
2004
187
0.050
Why?
CD3 Complex
2
2002
113
0.050
Why?
Immunity, Innate
2
2020
844
0.050
Why?
Receptor-CD3 Complex, Antigen, T-Cell
1
2002
9
0.050
Why?
Self Tolerance
1
2002
27
0.050
Why?
Cell Division
1
2004
736
0.050
Why?
Clone Cells
2
1998
259
0.040
Why?
Immunophenotyping
2
1998
324
0.040
Why?
Peptide Fragments
1
2004
693
0.040
Why?
Cytochrome c Group
1
2000
43
0.040
Why?
Phosphatidylserines
1
2000
62
0.040
Why?
Neoplasms, Experimental
1
1999
163
0.040
Why?
Antigens, Tumor-Associated, Carbohydrate
1
1998
8
0.040
Why?
Chondroitin Sulfate Proteoglycans
1
1998
10
0.040
Why?
Interphase
1
1998
38
0.040
Why?
Myeloid Cells
1
2020
149
0.040
Why?
Antigens, Differentiation, T-Lymphocyte
1
1998
106
0.030
Why?
Lymphocyte Count
1
1998
167
0.030
Why?
Hemagglutinin Glycoproteins, Influenza Virus
1
1998
34
0.030
Why?
Gene Expression
1
2023
1463
0.030
Why?
Oleic Acid
1
2017
40
0.030
Why?
Aged
1
2018
26432
0.030
Why?
Lipid Peroxidation
1
2017
168
0.030
Why?
Serogroup
1
2017
46
0.030
Why?
Bacterial Load
1
2017
68
0.030
Why?
Inflammation
1
2008
2919
0.030
Why?
Extracellular Space
1
2017
118
0.030
Why?
Interleukin-17
1
2017
121
0.030
Why?
DNA Replication
1
1998
248
0.030
Why?
Tumor Necrosis Factor-alpha
2
2017
1224
0.030
Why?
Cellular Microenvironment
1
2017
94
0.030
Why?
Virulence
1
2017
288
0.030
Why?
Adenosine Triphosphate
1
2017
494
0.030
Why?
Transcription Factors
1
2023
1730
0.030
Why?
Oxidation-Reduction
1
2017
1075
0.030
Why?
Proteins
1
1999
1022
0.020
Why?
Metabolome
1
2017
390
0.020
Why?
Interleukin-15 Receptor alpha Subunit
1
2012
1
0.020
Why?
Interleukin-2 Receptor beta Subunit
1
2012
23
0.020
Why?
Gene Expression Regulation, Neoplastic
1
1998
1432
0.020
Why?
Transplantation, Heterologous
1
2012
165
0.020
Why?
Fibroblasts
1
2017
1034
0.020
Why?
RNA, Messenger
1
1999
2791
0.020
Why?
Cyclosporine
1
2012
256
0.020
Why?
Metabolomics
1
2017
738
0.020
Why?
Bcl-2-Like Protein 11
1
2010
37
0.020
Why?
Macrophages
1
1998
1532
0.020
Why?
Graft vs Host Disease
1
2012
283
0.020
Why?
Coculture Techniques
1
2010
245
0.020
Why?
Apoptosis Regulatory Proteins
1
2010
186
0.020
Why?
Resting Phase, Cell Cycle
1
2009
16
0.020
Why?
Vaccinia virus
1
2009
35
0.020
Why?
Gene Deletion
1
2010
385
0.020
Why?
Algorithms
1
2017
1849
0.020
Why?
Tumor Cells, Cultured
2
1999
882
0.020
Why?
Proto-Oncogene Proteins
1
2010
616
0.020
Why?
Skin
1
2011
701
0.020
Why?
Intercellular Signaling Peptides and Proteins
1
2007
372
0.010
Why?
Inflammation Mediators
1
2008
508
0.010
Why?
Biomarkers
1
2017
4340
0.010
Why?
Antibodies
1
2007
400
0.010
Why?
Phosphorylation
1
2009
1724
0.010
Why?
Time Factors
2
2009
7109
0.010
Why?
Membrane Proteins
1
2010
1130
0.010
Why?
Cell Line
2
2000
2814
0.010
Why?
Crosses, Genetic
1
2003
120
0.010
Why?
Clonal Anergy
1
2003
55
0.010
Why?
Diabetes Mellitus, Type 2
1
2017
2623
0.010
Why?
Staurosporine
1
2000
22
0.010
Why?
Autoantibodies
1
2007
1500
0.010
Why?
Growth Substances
1
2000
136
0.010
Why?
fas Receptor
1
2000
91
0.010
Why?
Etoposide
1
2000
169
0.010
Why?
Membrane Potentials
1
2000
278
0.010
Why?
Versicans
1
1998
9
0.010
Why?
Hemagglutinins
1
1998
10
0.010
Why?
Injections, Intraperitoneal
1
1998
115
0.010
Why?
Nuclear Proteins
1
2003
740
0.010
Why?
Cell Line, Transformed
1
1998
137
0.010
Why?
Antigen-Presenting Cells
1
1998
161
0.010
Why?
Transfection
1
2000
916
0.010
Why?
Lymphoma
1
1998
251
0.010
Why?
Polymerase Chain Reaction
1
1999
1031
0.010
Why?
DNA-Binding Proteins
1
2003
1468
0.010
Why?
Immunoglobulin G
1
1998
901
0.010
Why?
Biomarkers, Tumor
1
1998
1339
0.010
Why?
Dooms's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)